Wilson Sonsini Goodrich & Rosati advised GI Windows Surgical on the transaction. Massachusetts-based GI Windows Surgical, a clinical-stage medical device company dedicated to developing the first...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised IonQ on the transaction. IonQ (NYSE: IONQ), a leader in quantum computing, announced that it has reached a definitive agreement...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented IVIVA in the transaction. United Therapeutics (Nasdaq:UTHR) announced it acquisition of all of the outstanding equity of IVIVA Medical, Inc., a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised NAPIGEN on the deal. NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed...
You must be a Standard 1 Year member to access this content.
